Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign

被引:1
|
作者
Gbenewei, Ene [1 ]
Nomhwange, Terna [2 ]
Taiwo, Lydia [3 ]
Ayodeji, Isiaka [2 ]
Yusuf, Kabir [1 ]
Baptiste, Anne E. Jean [2 ]
Nsubuga, Peter [4 ]
Braka, Fiona [2 ]
Oteri, Joseph [1 ]
Shuaib, Faisal [1 ]
机构
[1] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria
[2] WHO Country Off Nigeria, Abuja, Nigeria
[3] AFENET Country Off Nigeria, Abuja, Nigeria
[4] Global Hlth Solut, Atlanta, GA USA
关键词
AEFI (Adverse Event following Immunization); Measles; Supplemental immunization activities; Nigeria;
D O I
10.1016/j.vaccine.2021.02.067
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: An Adverse event following immunization (AEFI) is an untoward medical occurrence following immunization and which may not have a necessary causal relationship with the usage of a vaccine. The World Health Organization categories AEFI into two; serious and non-serious. An AEFI is considered serious if it is life-threatening, requires inpatient hospitalization or results in death. The measles vaccine is safe and effective however because it is a live-attenuated injectable vaccine it is more prone to AEFI as compared to non-injectable vaccines when given in large numbers over a short period as is the nature of measles mass vaccination campaigns (MVC). This article describes Nigeria's experience on AEFI reporting during the 2017/2018 Measles vaccination campaign (MVC). Methods: We reviewed various materials which included the Open Data Kit (ODK) which is an open source smartphone-based data collecting tool, operations room reports, measles campaign tally sheets, AEFI line listing forms, the post measles campaign coverage survey report and the report of the AEFI national expert committee review of the 2017/2018 Nigeria measles MVC. Results: A total of 6,214 suspected cases of AEFI were line listed from all 36 states and the Federal Capital Territory(FCT) during the 2017/2018 MVC with Fever(38%) and pain at injection site the (30%)most common reports. Overall, 99.7% AEFIs were reported to be non-serious AEFIs, with almost all cases resolved fully with no long-term sequalae.. The national incidence of suspected AEFI per 100,000 population was 16.3 with subnational incidence highest in Kebbi state (101.3/100,000) and lowest in Bayelsa state (0.8/100,000). Conclusion: Adequate AEFI reporting, Investigation and management remains important in managing the risk of a disruption of mass campaigns. The deployment of supervisors during campaign may play an important role in improving the identification and reporting of suspected AEFI. Further inquiries about AEFIs during the post campaign coverage evaluation also played a role in improving AEFI reporting and documentation. The real-time, on the spot, follow up by the national operations team helped with decision making and intervention including AEFI investigations and assessments. (C) 2021 World Health Organization. Published by Elsevier Ltd.
引用
收藏
页码:C82 / C88
页数:7
相关论文
共 50 条
  • [31] Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system
    Alguacil-Ramos, A. M.
    Muelas-Tirado, J.
    Garrigues-Pelufo, T. M.
    Portero-Alonso, A.
    Diez-Domingo, J.
    Pastor-Villalba, E.
    Lluch-Rodrigo, J. A.
    [J]. PUBLIC HEALTH, 2016, 135 : 66 - 74
  • [32] The average cost of measles cases and adverse events following vaccination in industrialised countries
    Hélène Carabin
    W John Edmunds
    Ulla Kou
    Susan van den Hof
    Van Hung Nguyen
    [J]. BMC Public Health, 2
  • [33] The average cost of measles cases and adverse events following vaccination in industrialised countries
    Carabin, H
    Edmunds, WJ
    Kou, U
    van den Hof, S
    Nguyen, VH
    [J]. BMC PUBLIC HEALTH, 2002, 2 (1) : 1 - 13
  • [34] Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017–2018
    Pedro Plans-Rubió
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1719 - 1729
  • [35] The world's largest measles-Rubella vaccination campaign in Pakistan: Time to invest in routine immunization
    Rana, Muhammad Suleman
    Usman, Muhammad
    Alam, Muhammad Masroor
    Ikram, Aamer
    Salman, Muhammad
    Umair, Massab
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [36] Implementation and evaluation of a measles/rubella vaccination campaign in a campus university in the UK following an outbreak of rubella
    Stevenson, J
    Murdoch, G
    Riley, A
    Duncan, B
    McWhirter, M
    Christie, P
    [J]. EPIDEMIOLOGY AND INFECTION, 1998, 121 (01): : 157 - 164
  • [37] Surveillance of Adverse Events Following Immunization (AEFI) with Trivalent Inactivated Influenza Vaccine in Canada: Was an Increase in the Number of Febrile Seizures Observed for the 2010-2011 Vaccination Campaign?
    Lafleche, J.
    Pless, R.
    Law, B.
    [J]. DRUG SAFETY, 2011, 34 (10) : 927 - 928
  • [38] Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017-2018
    Plans-Rubio, Pedro
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (09) : 1719 - 1729
  • [39] Epidemiological characteristics of measles from 2000 to 2014: Results of a measles catch-up vaccination campaign in Xianyang, China
    Zhang, Rong-Qiang
    Li, Hong-Bing
    Li, Feng-Ying
    Han, Li-Xin
    Xiongo, Yong-Min
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2017, 10 (05) : 624 - 629
  • [40] Measles outbreak linked to insufficient vaccination coverage in Nouvelle-Aquitaine Region, France, October 2017 to July 2018
    Bernadou, Anne
    Astrugue, Cyril
    Mechain, Matthieu
    Le Galliard, Valerie
    Verdun-Esquer, Catherine
    Dupuy, France
    Dina, Julia
    Ait-Belghiti, Fatima
    Antona, Denise
    Vandentorren, Stephanie
    [J]. EUROSURVEILLANCE, 2018, 23 (30):